【首个国产司美格鲁肽上市申请未获批准】金十数据12月31日讯,国家药监局12月31日药品通知件送达信息显示:九源基因的司美格鲁肽注射液在列,意味着该产品暂时未获批准。今年4月2日,九源基因递交了司美格鲁肽注射液的上市申请并获受理,这也是国内第一家申报上市的司美格鲁肽生物类似药。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.